Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

Moderna has gotten torched over the last six months - since September 2024, its stock price has dropped 51.2% to $33.99 per ...

LEXINGTON, Mass., March 11, 2025 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company ...

CompanyOverview|NASDAQ:MRNA] The CEO of Moderna Inc. (NASDAQ: MRNA) just purchased $5 million of stock in the open market.

BioNTech SE exceeded earnings expectations with strong oncology pipeline development, despite reduced vaccine revenue.

Learn more about whether Ionis Pharmaceuticals, Inc. or Sarepta Therapeutics, Inc. is a better investment based on AAII's A+ ...

Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...

Moderna, Inc. (NASDAQ:MRNA – Get Free Report) saw unusually large options trading activity on Thursday. Stock investors purchased 143,752 call options on the company. This represents an increase of ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

Moderna's legal win boosts stock but highlights mRNA technology struggles. Discover why MRNA stock may not sustain long-term ...

The surge in MRNA stock comes after some SEC filings show that company insiders bought shares worth $6 million.

Moderna, Inc. (NASDAQ:MRNA) shares rose for a second day on Wednesday, adding 15.94 percent to finish at $35.21 apiece as ...